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ABSTRACT 
Electronic nose (e-Nose) is an innovative biomimetic method that simulate the 
human olfactory system to identify the quality of odors, through a nano-sensor 
system in combination with specific processing algorithms. 
The instruments used are electronic devices characterized by complex 
architectures. 
The electronic nose can detect volatile organic compounds (VOCs) derives from 
hydrocarbons such as formaldehyde, methanol, ethanol, hydrogen sulphate, 
benzene, acetaldehyde, acetone, toluene, phenols produced during metabolic, 
inflammatory and oxidative stress. 
In general, this tool does not allow to identify a single VOC but defines the 
characteristics of a group of VOCs defining a specific profile. 
The sample to analyzed is exposed to the 32 nano-sensors resulting in the 
modification of the basal resistances and its electrical conductivity. 
There are several applications of this technology in the medical field in particular 
pneumology for the characterization of various disease (sarcoidosis, COPD, 
asthma, obstructive sleep disorders) as demonstrated by several studies on adult 
patients. In the literature, only a few studies have been conducted on pediatric 
subjects, particularly in patients undergoing mechanical ventilation, therefore data 
on spontaneous breathing is not available and standardization of the method in 
this age group is not yet available. 
The exhaled air contains more than 200 volatile organic substances (VOCs), many 
of which derive from the metabolism of endogenous substances and others from 
external contaminants (xenobiotic compounds). Exhaled air analysis is a new 
approach to evaluating metabolic disorders related to various diseases, eg. lung 
cancer, asthma, cystic fibrosis. 
The purpose of our study is assessing the feasibility of the method on pediatric 
patients and to define any limits in the collection of the samples. Then evaluate if 
there are different respiratory pattern due to a different composition of VOCs 
based on the respiratory pathology of the patient.  
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This study has laid the ground for further refinement in the standardization of 
exhaled sample collection in pediatric subjects and the evaluation of pediatric 
disease.  
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SOMMARIO 
Il naso elettronico (e-Nose) rappresenta una metodica innovativa biomimetica che 
permette di simulare il sistema olfattivo umano nel verificare la qualità degli odori 
attraverso l’utilizzo di un sistema di nano-sensori in combinazione con specifici 
algoritmi di rielaborazione. 
Le strumentazioni utilizzate sono apparecchi elettronici caratterizzati da 
architetture complesse.  
Il naso elettronico è in grado di rilevare i composti organici volatili (VOCs) 
derivanti dagli idrocarburi come ad esempio formaldeide, metanolo, etanolo, 
solfato di idrogeno, benzene, acetaldeide, acetone, toluene, fenoli che vengono 
prodotti durante i processi metabolici, infiammatori e nello stress ossidativo. 
In linea generale tale strumento non permette di identificare un singolo VOC ma 
definisce le caratteristiche di un gruppo di VOCs attraverso la definizione di un 
profilo specifico. 
L’esposizione del campione da analizzare ai 32 sensori dello strumento provoca 
una modificazione delle resistenze basali modificandone la conduttività elettrica. 
Diverse sono le applicazioni di questa tecnologia nell’ambito medico in campo 
pneumologico per la caratterizzazione di diverse patologie (sarcoidosi, COPD, 
asma, patologie ostruttive del sonno) così come dimostrato da diversi studi su 
pazienti adulti. In letteratura solo pochi studi sono stati condotti su soggetti 
pediatrici, in particolare in pazienti sottoposti a ventilazione meccanica, pertanto 
non sono disponibili dati su pazienti in respiro spontaneo e non è ancora 
disponibile una standardizzazione della metodica in questa fascia di età.  
L’aria esalata, contiene più di 200 sostanze organiche volatili (VOCs) presenti in 
tracce, molte delle quali derivanti dal metabolismo di sostanze endogene ed altre 
provenienti da contaminazioni esterne (composti xenobiotici). L’analisi dell’aria 
espirata, rappresenta un nuovo approccio per la valutazione di alterazioni 
metaboliche legate a diverse malattie, es. tumore polmonare, asma, fibrosi cistica. 
Lo scopo del nostro studio è quindi quello valutare innanzitutto la fattibilità della 
metodica in ambito pediatrico e definirne eventuali limiti nella raccolta dei 
campioni. Successivamente valutare se possono esistere differenti pattern 
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respiratori riconducibili a una differente composizione di VOCs sulla base della 
patologia respiratoria del paziente.  
Questo studio ha gettato le basi per ulteriori approfondimenti nell’ambito della 
standardizzazione della raccolta del campione di esalato in soggetti e lo studio 
delle principali patologie pediatriche. 
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INTRODUCTION 
NON-INVASIVE INFLAMMATORY BIOMARKERS IN LUNG 
PATHOLOGIES 
Biomarkers are objectively and measurable indicators of the biological and 
pathological processes or pharmacological responses to a therapeutic intervention 
(Kharitonov et al. 2001). Measure the biomarkers in exhaled breath is a very 
attractive approach to monitor airways inflammation in asthma and other lung 
diseases.  
The methods are not invasive, feasible also in pediatric population, and make 
sampling repeatable (Kharitonov et al. 2001) (Barnes et al 2006). However, there 
are important issues regarding reproducibility, variability and sensibilities that 
need to be assessed before the collection and are recommended in clinical 
practice. Nowadays there are relatively few knowledges about how these 
biomarkers interact each other in the illness evolution, how they can act in the 
severity of disease or clinical subtypes or response to therapy. In the future, these 
new techniques may be useful to predict the progression of the disease, to evaluate 
the response to current and future therapies, many of which are still in place way 
of development. 
However, lung function and symptoms not always reflect the underlying airway 
inflammation and response to therapy (Vijverberg et al. 2013) (Murugan et al. 
2009); therefore, objective parameters of asthma inflammation could be important 
for the clinician when making a treatment choice.   
Currently, diagnostic methods like bronchoalveolar lavage (BAL) and 
bronchoscopy are the gold standard for assessing airway remodeling and 
inflammation in lung disease. These methods, however, are too invasive and have 
a limited use, especially in pediatric care (Vijverberg et al. 2013). For these 
reasons, in the past years, research studies have focused on objective biomarkers 
to identify phenotype, inflammation, pathobiological pathways and to guide the 
clinician in the diagnosis and a personalized management of the disease (Moore et 
al. 2010) (Erzurum et al. 2012).  
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An ideal biomarker is easy to collect and measure, inexpensive, non-invasive, 
feasible in children and technically simple to applied in the clinical setting or in 
the treatment response evaluation.  
The induced sputum technique can be considered a surrogate non-invasive method 
to evaluate airway inflammation. Nevertheless, this technique may be difficult to 
perform in pediatric patients and therefore its clinical application is still limited.  
Exhaled breath condensate (EBC) and the measurement of exhaled nitric oxide 
(FeNO) are currently the most frequently used tests in clinical practice (Baraldi et 
al. 2006) and are feasible in the pediatric population.  
FeNO is an extensively studied marker and its clinical usefulness is supported by 
guidelines (ATS guidelines 2005). However, studies about the correlation between 
FeNO and asthma control or its effectiveness in the management of asthma 
treatment are contradictory (Raymer et al. 1990) (Deykin et al. 2002).  
FeNO can be helpful to evaluate asthma control in asthmatic patients and 
monitoring asthmatic patients in treatment. However, its suboptimal sensitivity 
and specificity may limit its utilization as a single monitoring tool. 
On the other hand, although the efficacy and diagnostic roles of inflammatory 
markers in exhaled breath condensate have been studied, their clinical use is still 
under debate (Robroeks et al. 2010) (Fens et al. 2009).  
In diagnose and monitoring asthma, an approach that involves an ensemble of 
EBC biomarkers had better accuracy in real-life settings than a single marker. A 
poor to moderate association of EBC biomarkers with lung function suggests the 
greater importance of EBC analysis in the diagnosis of asthma in children. 
Other markers that might predict asthma exacerbation are volatile organic 
compounds (VOCs) that reflect the degree of airway inflammation and asthma 
control (Robroeks et al. 2010). VOCs in exhaled breath showed a potential role in 
predicting asthma exacerbations in children. Before adopting VOCS analysis in 
clinical practice, the validity of their capacity to predict asthma exacerbations 
should be studied in a larger cohort. 
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Fractional exhaled nitric oxide (FeNO) 
In the airways, nitric oxide is mainly produced by two enzymes: constitutive nitric 
oxide synthase (cNOS) that generates low quantities of NO and epithelial 
inducible NOS (iNOS) that is induced by various inflammatory cytokines (Turner 
2015).  
 
 
 
 
Fig. 1: FeNO pathways in health and asthmatic (from Alving et al, 2010) 
 
The exhaled fraction of nitric oxide was extensively studied in asthma and has 
been demonstrated the correlation with eosinophilic airways inflammation 
pathways and its subsequent decrease after corticosteroid therapy (ATS Workshop 
proceedings 2006). 
FeNO has been recognized as a marker of eosinophilic airway inflammation and 
its measurement has been proposed to assess the level of airway inflammation and 
the response to anti-inflammatory therapy (Kharitonov et al. 1996).  
12 
 
FeNO measurement is a non-invasive, repeatable and reproducible method 
(Pijnenburg et al. 2008). The gold standard for cooperative children is the single 
breath on-line method (Baraldi et al. 2002). Other techniques have been evaluated 
for uncooperative children or in sedated infants (Baraldi et al. 2002).   
On-line and off-line methods have both been used in uncooperative children 
without the use of sedatives. Limited experience has been described using single-
breath methods in infants. However, these methods have never been validated for 
clinical purposes and further researches are needed to define standardized 
measurements in this age group.  
At present, no clear evidence is available regarding the potential clinical 
application of NO measurements in uncooperative children, particularly regarding 
its potential application in association with other diagnostic tests, to predict 
asthma in young children (Moschino et al. 2015). 
To standardize FeNo measurement procedures, an initial document on FeNO 
measurement in children was published in 2002 (Baraldi et al. 2002), which was 
jointly revised by ATS/ERS in 2005 (ATS guidelines 2005). The standardization 
of techniques may permit to collect comparable data in different centers for 
normal subjects and for those with diseases. FeNO levels can be influenced by 
various factors such as exhalation flow, nasal contamination, ambient air 
pollution, patient’s age, height, gender and race (ATS guidelines. 2005). 
Furthermore, spirometry or exercise performed before the measurement, diet or 
exposure to smoke also need to be considered. 
In children, FeNO increases with age, as reported in the literature (ATS guidelines. 
2005), and it is recommended that NO analysis should be performed before 
spirometry because it has been shown that can cause a reduction in transient 
exhaled NO levels (ATS guidelines. 2005). Patients should also desist from eating 
and drinking before NO analysis. An increase in FeNO has been found after 
ingestion of nitrate or nitrate-containing foods. Several studies demonstrated that 
FeNO correlates positively with airway hyper responsiveness, IgE serum levels, 
broncho-dilator response, skin prick tests, asthma symptoms and lung function 
(Covar et al.  2003) (Komakula et al. 2007).  
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In allergic asthma, airway inflammation results from the activation of mast cells 
and Th2-mediated pro-inflammatory cytokine mechanism that results in the 
production of IL-4, IL-5, and IL-13 which cause epithelial inducible NO synthase 
expression that up-regulated via STAT-6, through corticosteroid sensitive process, 
a mechanism of central importance in allergic airway inflammation (Ludviksdottir 
et al. 2012) (Mahr et al. 2013) (see fig.1). Moreover, other studies showed that 
FeNO levels are correlated with eosinophils in induced sputum, eosinophil 
infiltration in the airways, blood eosinophilia, serum eosinophilic cation protein 
and IgE levels in atopic patients (Mahr et al. 2013). Asthma phenotype 
characterized by Th2-mediated airway inflammation, eosinophilia, and 
responsiveness to ICS shows high FeNO values (Mahr et al. 2013).  
In addition to clinical history and lung function test, FeNo is also helpful in 
identifying patients with asthma eosinophilic phenotype and in predicting asthma 
exacerbation.  
The ATS guidelines recommend the use of FeNO to monitor airway inflammation 
and to guide anti-inflammatory treatment in patients with asthma (Mahr et al. 
2013). High FeNO values, however, are associated with allergic rhinitis, 
eosinophilic bronchitis and allergen or viral exposure; it is important to remind 
that not all high FeNO values are linked to eosinophilic asthma. The ATS/ERS 
document stresses the relevance of a correct interpretation of FeNO values (Dweik 
et al. 2011).  
In children, FeNO values lower than 20 ppb are probably correlated to absence of 
response to ICS treatment. On the other hand, FeNO over 35 ppb suggests a 
response to ICS supporting its role in identifying Th2 airway inflammation 
responding to ICS treatment (Mahr et al. 2013). It has been widely demonstrated 
that there is a rapid decrease in FeNO when ICS treatment is started, with a dose-
dependent mechanism, and a sudden rise when ICS therapy is interrupted (van 
Rensen et al. 1999). This trend may be helpful to monitoring patient compliance 
to therapy (Pijnenburg et al. 2008).  
FeNO can also be used in patients in treatment with omalizumab. In fact, some 
studies showed that FeNO values together with blood eosinophils and BMI can 
predict response to omalizumab (Sorkness et al. 2013). Experimental data in 
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adults also showed that high FeNO values may indicate a response to treatment 
with human anti-interleukin-4 receptor monoclonal antibodies that inhibits 
interleukin-4 and interleukin-13 signaling way (Wenzel et al. 2016).  
Despite the initial enthusiasm about FeNO in the management of asthma in 
children, the literature is very careful to support the use of FeNO in addition to 
standard symptom-based management (Petsky et al. 2012) (Jartti et al. 2012), and 
its utilization is now being reviewed and is under debate (Bjermer et al. 2014). 
Therefore, in clinical practice, FeNO may be considered a clinically useful 
method to identify patients with eosinophilic and Th2-mediated asthma, who are 
expected to respond to ICS therapy. Furthermore, it may have a practical role in 
predicting exacerbations and patient compliance to therapy.  
 
Exhaled breath volatile organic compounds 
Exhaled breath volatile organic compounds (VOCs) derive from metabolic 
fractioning of larger molecules. Airway VOCs originate not only from the upper 
and lower respiratory airways but also from the capillary bed near the alveoli (van 
Mastrigt et al. 2015). The measurement of VOCs is recently proposed in research 
and clinical setting to evaluated respiratory and non-respiratory diseases. The 
methodical approach to collect VOCs from exhaled breath requires attention to 
exclude from ambient air the organic compounds (van Mastrigt et al. 2015).  
The collection of airway VOCs may be performed by on-line methods, which 
allow the technician to directly collect samples via inert tubes inserted into an 
analyzer, or off-line methods which involve the collection of exhaled air into 
bags, tubes or syringes. Collection devices need to be made from inert materials 
such as Tedlar bags (Barker et al. 2006).  
After collecting the sample, different techniques can be used to analyze the 
specific content.  
Gas chromatography and gas spectrometry (GC-MS) or flame ionization detection 
(GC-FID) are the most extensively used techniques. These methods can 
distinguish and quantify VOCs at low concentrations, but they require highly 
qualified technicians and expensive device (Moschino et al. 2015).   
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A new non-selective approach to analyze VOCs in exhaled breath is 
metabolomics technique, that identify and quantify all metabolites in a biological 
sample, without a priori hypothesis. Metabolomic profiles represent the 
interaction between genetic expression, environmental exposure, microorganisms, 
medication, nutrition and toxic substances (Moschino et al. 2015) (van Mastrigt et 
al. 2015). This method allows to define disease phenotype and permits the 
characterization and personalized therapy for the patient. This approach 
simultaneously evaluates many metabolites in a sample and generates metabolite 
profiles that discriminate between different groups of individuals, providing a 
defining all the biochemical processes underway in a given biological system. 
More recently, simpler devices with sensor-based techniques such as electronic 
nose, colorimetric sensor array and gold nanoparticle sensors have been proposed. 
They use specific sensors with optical, chemical or electronic properties that can 
detect and cluster VOCs in the exhaled breath (EB) (van Mastrigt et al. 2015). In 
recent years, several studies have demonstrated the clinical application of these 
instruments in respiratory disease and allergy (Dallinga et al. 2010) (Caldeira et l 
2011).  
VOCs in the EB can discriminate patients with asthma from healthy children and 
atopic from non-atopic children (Dallinga et al. 2010). In children, VOCs have 
also been reported as can predict asthma exacerbations (Robroeks et al. 2013). 
VOCs collection is also possible in preschool children and their profiles have been 
shown to be different in children with recurrent wheezing as compared to 
controls. 
Nevertheless, further studies are necessary principally to evaluate the clinical 
usefulness of VOCs assessment in assessing asthma severity and monitoring 
asthma symptoms and response to ICS therapy. 
 
Exhaled breath condensate 
Exhaled breath condensate (EBC) is a non-invasive method to evaluate airway 
inflammation analyzing markers of inflammation that can help to understand 
asthma pathophysiology. EBC is composed of elements from airway lining fluid 
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collected by the condensation of warm humid breath into a cold surface in a 
condensing device.  
 
 
 
 
 
 
 
 
 
 
Fig.2: Refrigerate device use in clinical practice 
 
EBC is composed of water vapor, unstable volatiles like CO2 and H2O2, inorganic 
(O2, N2) and organic (CO2) particles, exogenous and endogenous organic 
compounds, protein and cytokines (Dent et al. 2013). In the respiratory system, 
H2O2 may be released from inflamed cells, including neutrophils, macrophages, 
eosinophils, and epithelial cells. Nitrogen redox forms such as nitrite (NO2 -) and 
nitrate (NO3 -) are present in the epithelial lining fluid of the human respiratory 
tract. 
Concentrations of NO2 and NO2+NO3 were significantly higher in cases of 
asthma, CF and bronchiectasis compared with healthy controls (Dent et al. 2013). 
EBC collection is typically done using a refrigerated device in compliance with 
ATS/ERS guidelines (Horváth et al. 2005). It involves 10-15 minutes of tidal 
breathing during which the airways lining fluid undergoes an aerosolizing process 
and is then condensed in a cooled device (0 to -20°C) (Baraldi et al. 2006).  
The most frequently evaluated parameters in EBC are pH, exhaled markers of 
oxidative stress and inflammation. 
EBC pH is considered a non-specific marker of airway disease and normative data 
have been published for children from 0 to 20 years, with a median pH value of 
8.0 (Paget-Brown et al. 2006). Some studies reported that children with stable 
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asthma had a lower pH in EBC than healthy controls and those suffering from 
severe asthma had a lower pH value than mild asthmatics (Carraro et al. 2005) 
(Brunetti at al. 2008). In addition, asthmatic patients had a lower pH than those 
ICS treated, and those with acute exacerbation had a higher pH after treatment 
with budesonide (Carraro et al. 2005) (Brunetti at al. 2008).  
Acidification has also been reported in children with allergic rhinitis and atopic 
dermatitis (Brunetti at al. 2008).   
At present, no correlation has been reported with asthma symptoms, lung 
function, FeNO or airway hyperresponsiveness (Rosias et al. 2004) (Ratnawati et 
al. 2006).  
An important set of potential biomarkers in EBC is related to oxidative stress like 
H2O2, 8-isoprostane, asymmetric dimethylarginine (ADMA), aldehydes and 
nitrite/nitrate.  
H2O2 in EBC is released from inflamed airways as superoxide anions, an unstable 
and reactive particle. In the respiratory system, H2O2 can be released from both 
inflammatory cells (neutrophils, macrophages, eosinophils) and epithelial cells. 
The normal level of this molecule in young, non-asthmatic and non-smoking 
children is 0.09 µmol (Horváth et al. 2005). H2O2 was found to be higher in 
asthmatic children during exacerbations and decreased after ICS treatment, which 
emphasized the hypothesis that H2O2 is a marker of airways inflammation. 
However, other studies don’t demonstrate a significant difference in H2O2 
between asthmatics and controls or in its capacity to predict exacerbations 
(Trischler et al. 2012) (Robroeks et al. 2012). 
Asymmetric dimethylarginine (ADMA) is another potential marker of oxidative 
stress identifiable in EBC by the UPLC-MS/MS technique. It is an analogue of L-
arginine that reduces, by inhibiting NOS, the synthesis of NO and increases 
superoxide. Asthmatic children showed higher values of ADMA than healthy 
ones with no difference related to ICS treatment (Carraro et al. 2013).  
Aldehydes and lipid hydroperoxides derive from the oxidation of the phospholipid 
membrane and polyunsaturated fatty acid.  
A study showed high levels of glutathione in the EBC of asthmatic children with 
exacerbation. That study reported that after 5 days of prednisolone therapy the 
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malondialdehyde level fell, while glutathione rose (Corradi et al. 2003). These 
results suggest that in exacerbations of asthmatic patients there is a disparity 
between oxidative and antioxidant agents. In children with asthma, 
malondialdehyde levels is associated with air pollution, lung function and 
inflammatory markers (Romieu et al. 2008).  
8-isoprostane is a product of arachidonic acid and it is also an indicator of 
oxidative stress (Moschino et al. 2015). Children and adults with asthma present 
high levels of this marker, during severe asthma or asthma exacerbations (Baraldi 
et al. 2003). The concentrations of 8-isoprostane have no correlation with ICS or 
leukotriene receptor antagonist therapy, lung function or FeNO.  
Eicosanoids are a large group of markers derived from arachidonic acid that play a 
role in asthmatic inflammation. The presence of these markers in EBC can be 
confirmed by specific enzyme immunoassay and radio immunoassays (Thomas et 
al. 2013).  
In children with asthma leukotriene B4 (LTB4), cysteine leukotrienes (LTC4, 
LTD4 and LTE4) are high in EBC compared to healthy subjects (Thomas et al. 
2013). The role of cysteine leukotrienes (CysLT) in response to ICS therapy is 
under debate (Csoma et al. 2002) (Debley et al. 2007) (Steiss et al. 2008). Some 
authors report a significant reduction of CysLT after a course of oral steroids or 6 
months of ICS therapy, whereas others report no changes. A significant reduction 
of CysLTs has been reported after Montelukast treatment(Montuschi et al. 2006).  
Several other markers of inflammation and oxidative stress such as cytokines and 
adenosine have been studied.  
Th2 cytokines are assessed using the ELISA technique.  Some studies showed that 
the number of Th2 cytokines is higher and Th1 cytokines is lower in the EBC of 
asthmatic children (Karakoc et a. 2012) (Shahid et al. 2002). IL-4 was higher in 
asthmatic children, especially in atopic, and it has been proposed as a predictor for 
asthma diagnosis, and IL-5 to predict asthma exacerbations (Robroeks et al. 
2012).  Children with asthma have also been reported to present with a higher IL-
4/INFγ ratio related to Th2 inflammation (Shahid et al. 2002). 
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ELECTRONIC NOSE TECHNOLOGY 
The e-nose analysis: rationale & applicative issues 
Breath analysis performed for medical aims represents one of the most ancient 
clinical objectives. 
Smelling breath to diagnose diseases derives from the ancient medicine. Past 
physicians knew that several diseases alter the odor of a patient’s breath such as 
diabetes, liver diseases and kidney diseases.  
The history of medicine since Hippocrates, during the 4th century BC, describes 
the use of the smell of patients to assess their health status. 
A few centuries later, Galenus (2nd century AD) was able to compare breath 
odors from kidney or liver diseases, and in the 18th century acetonemic smell in 
breath has been used to define diabetic ketoacidosis. 
Exhaled breath contains thousands of VOCs with exogenous and endogenous 
origin. Endogenous ones are associated to the physiological and pathological 
processes of the human body and are not only from the airway tract (Haick et al. 
2014).  
The analysis of VOCs is a non-invasive method to study metabolic, oxidative 
stress-related and inflammatory processes in the organism, usually linked with 
several biochemical reactions.  
Therefore, the capacity to define pattern of exhaled VOCs to specific clinical 
conditions could accelerate and simplify clinical approach for diagnosis and 
monitoring a disease. The breath analysis principle is based on the physiology of 
olfactory system and, by the application of modern artificial sensors technology, 
with the purposes to create devices able to identify volatile compounds of clinical 
interest, even those that are not detected by human smell (e.g., nitric oxide). 
The term ‘electronic nose’ (e-nose) is known since 1988 and was introduced by 
Gardner and Bartlett, who defined it as ‘an instrument that comprises an array of 
electronic chemical sensors with partial specificity and appropriate pattern 
recognition system, capable of recognizing simple or complex «odors»’ (Gardner 
et al. 1994).  
The interest in the electronic nose is demonstrated by many scientific articles that 
explain and use this new technology in research in medical and clinical practical 
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applications. E-nose and VOCs analysis were also being applied in different fields 
such us for volatile emissions assessments, homeland security, environmental 
protection, biomedical diagnoses, personnel safety and in product development 
research (Scarlata et al. 2015).  
Breath analysis aims to identify compounds in different samples of exhaled breath 
to recognize and differentiate physiologic and pathologic conditions. A crucial 
question is the identification of the VOCs in the complex exhaled breath mixture. 
Only 1% of the about 3000 different compounds present in human breath is 
shared to all individuals (Horvarth et al. 2009), whereas the other mixtures are 
formed from the interaction between human behaviors, environment factors, and 
lifestyles. Identify disease markers in or out of that 1% is not the ability of e-nose 
technology because it doesn’t identify the specific molecules. 
Gas chromatography (GC) approach consents the identification of each single 
VOC in different group of patients (e.g., healthy/diseased) (Scarlata et al. 2015).  
Mass spectrometry lets the measurement of low-molecular-weight particle to 
identify metabolites that are correlated with a specific illness.  
Most popular current VOCs analysis are based on the analysis of each 
compounds, however an approach that evaluated the mixture of compounds may 
offer more information on the differences between subjects with different 
diseases. In this perspective, breath analysis is a ‘pattern recognition’ problem 
where the acquired patterns are related to a population of samples. 
Electronic noses represent an innovative, relatively cheap and easy technique for 
VOCs pattern analysis (Montuschi et al. 2013). The device is characterized by a 
sensor array and an in-built processor (Rock et al. 208). Functionally they are like 
the biological olfactory receptors and cannot recognize singular VOC but are able 
to relate molecular patterns and discriminate exhaled gaseous samples based on 
their molecular fingerprints. The exhaled volatile compound pattern is frequently 
referred to as ‘breathprint’ (Bikov et al. 2015).  
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Fig. 3: The mixture of the signal from all sensors generates the so-called “breathprint” 
(from Dragonieri et al, 2016) 
 
Existing devices 
The devices for VOC collection/analysis now existing are summarized in table 1. 
 
Table 1: Current available devices (from Scarlata et al, 2015) 
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Some devices are commercially available but others, those with nonchemical 
sensors, are prototypes developed by different centers working in this field 
(Scarlata et al. 2015). 
The kind of sensor technology used play an important role in the exhaled breath 
analysis.  
The common sensors used in exhaled breath analysis are made with sensitive 
materials obtained from organic molecules (organometallic compounds and 
polymers) that are very conductive and permit to transducer the signal based on 
mass variations or on optical properties (Scarlata et al. 2015). 
The combination between organic molecules and gold nanoparticles or carbon-
black allow the sensors to transform the chemical signal in an electric resistance 
change. These sensors in e-nose are usually minor than hundred and are not 108 
as in the human olfactory system.  
Each sensor of the e-nose is composed by sensitive material that ‘translates’ the 
variation of chemical signal into an optical or electrical signal. Electronic device 
allows the recognition and amplification of very low concentrations of VOCs. The 
final output must be analyzed using multivariate data analysis techniques. 
 
 
 
Fig.4: steps in electronic nose measurement (Scarlata et al. 2015) 
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Sensor systems in Cyranose 320® 
The most usually used electronic nose in respiratory disease is Cyranose 320® 
that is applied in different research laboratory and studies. The instrument has an 
optimal number and arrangement of sensors, sensor layer material and vacuum 
pressure (Lewis et al. 2004).  
 
 
Fig.5: Cyranose 320 
 
Cyranose 320® is characterized by a carbon black conducting polymer array of 32 
sensors which work on electrical resistance changes from steady-state induced by 
the volatile particle exposure to the sensor (Lewis et al. 2004).  
The sample is aspirated, during the measurement, by an in-built pump, and VOCs 
induced swelling of the polymer film. 
This increases the electrical resistance of the composite which produces an 
electrical signal.  
Sensor responses (dR) are computed based on the change in resistance caused by 
the attachment of molecule and background according to the following formula: 
 
dR = (Rs − R)/R 
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where Rs is the response to the sampled gas and R is the response to the baseline 
reading. 
Molecules produce different responses based on their chemical characteristic such 
as molecular shape, size, volume, dipole moment and hydrogen bonding capacity 
(Lewis et al. 2004). The sensors response to VOCs is a linear combination of 
responses to analytes together by the mole fraction absorbed into the polymer and 
the concentration of the volatile substance and are independent from the 
background (Hopkins et al. 2001).  
Cyranose 320 can differentiate volatile substances in the concentration range 
between 100 ppb and 100 ppm.  
The selectivity of carbon black polymer sensors for volatile substances is not 
influenced by humidity in exhaled breath but the rise of water vapor pressure 
decreases its sensitivity (Hopkins et al. 2001).  
This possible confounding factor may be resolved excluding from analysis sensors 
5, 6, 23, 31 that are the most sensitive to the water sensors in Cyranose 320 
(Maciejak et al. 2002).  
The polymer sensors are also influenced by the temperature of the sample gas, so 
monitoring temperature is mandatory during analysis (Knobloch et al. 2009). 
 
Technical issues: Breath sampling systems, available devices for 
collection and storage 
The procedure of exhaled breath analysis by an electronic nose needs to consider 
some important and critical aspects: 
 
✓ contamination of the sample by exogenous VOCs; 
✓ collection and storage methods; 
✓ standardization and reproducibility of the procedure. 
 
Contamination of the sample by exogenous VOCs: 
Exogenous volatile compounds in the exhaled breath can be reduced by using 
specific filter that purified the air before entering in the system (wash-in 
procedure) or pre-breathing the air purified by the subject and/or using a 
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restrictive protocol for the subject pretreatment in relation to food or drinks intake 
before the examination (Gordon et al. 1985) (Dragonieri et al. 2009).  
The wash-in approach needs specific equipment and often is not possible in 
clinical practice. The patients absorb volatile exogenous compounds also by 
through the skin and then they excreted in the breath and that are not eliminable.  
Another method, easier, to remove exogenous VOCs includes the use of a 
cartridge (Cartridge N7500-2; North Safety Products, Cranston, RI, see figure 6), 
connected in series to the inspiratory system of the sampling mechanism. This 
cartridge can remove 99.99% of the VOCs present in the inhaled air (Kataoka et 
al. 2013) (Spanel et al. 2013). 
 
 
Fig. 6: Cartridge 
 
Nowadays it is undefined the use of nose clips in the influence sampling in 
electronic nose analysis, but it is used in exhaled breath condensate (EBC) 
analysis (Philips et al.1997).  
Ambient air, particularly in laboratories and hospitals, may contain variably high 
levels of acetone, acids, aldehydes and benzene derivates so a filter may be used 
to exclude them from exhaled breath (Bajtarevic et al. 2009). 
In literature two procedures are described to collect the alveolar air sampling. The 
first one needs that the subject exhale the entire vital capacity through a 
mouthpiece connected to a 2-way valve (Vitalgraph, Maids Moreton, UK; Hans 
Rudolph 2700, Hans Rudolph, Kansas City, MO) (Kataoka et al. 2013), 
connected in series with a filter for inhaled VOCs (A2, North Safety, Middelburg, 
NL) (Buszewski et al. 2007) and to a system (silica gel) for eliminating water from 
the sample. A specify bag for the collection of the sample completes the system 
(fig. 7).  
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Fig.7: System to collect the sample 
 
In the second procedure, the mouthpiece is connected to a filter for VOCs and to a 
three-way valve (D’Amico et al. 2010). The two free outputs of the valve are 
linked to a collection bag. The air can easily enter the first bag, while a valve 
prevents access to the second one. When the volume in the first bag reaches the 
estimated volume of the dead space, alveolar air can enter the second bag (de Lacy 
Costello et al. 2014) (van de Kant et al. 2012). 
Exhaled VOCs can be measured also in real-time, during exhalation, without the 
problems related to storage and breath-to breath variations. Therefore, in research 
studies sampling from bags is more common. 
The collection of breath air depends on the sampled volume of exhaled breath: 
alveolar air, or air from both alveolar air and respiratory dead space (mixed air). 
Mixed air is easier to be collected but at more risk of contamination by external 
agents.  
Mixed air provides more information in asthma, alveolar air to diagnose lung 
cancer (Montuschi et al. 2010) (Santonico et al. 2012). 
The kinetics of VOC from the airways may change at various flow rates, but 
proper modelling for VOC flow-dependence has not been done (Boshier et al 
2011). 
 
Mouthpiece connected to a 2-way valve 
Filter for 
VOCs 
Bag for the 
collection 
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Representative collection and storage methods 
Plastic bags internally covered with chemically inert materials such as polyvinyl 
fluoride (PVF, Tedlar), polytetrafluoroethylene (Teflon), polyester-aluminum, 
polyethylene terephthalate (Mylar, Nalophan) are usually used for collecting and 
stored the exhaled breath. Tedlar bag are the most usually used.   
Some attentions to the environment status must be taken in consideration: direct 
exposure to sunlight or uncontrolled heating may cause the emission of 
hydrocarbons, nitrogen, N-dimethylacetamide and phenols from these bags. 
VOCs when collected into the Tedlar bags reduce over time their concentration, 
the volume decreases by 10% of the starting sample 52 h after collection. 
The sampling bags are very cheap but not consent the preservation of breath 
samples for more than a few hours (six hours in Tedlar bags) (Amman et al. 
2010).  
 
Standardization and reproducibility of the procedure 
In clinical practice standardization and reproducibility are crucial during a 
measuring process.  
The lack of an acceptable level of standardization does not permit to replicate the 
results and so the procedure is impossible to be considered feasible for routine 
clinical practice. 
The reproducibility of measurements, also, should be considered of pivotal 
importance (Bikov et al. 2015). 
Some studies examined the reproducibility of Cyranose 320 by repetitive breath 
monitoring and both a good short- and long-term reproducibility was reported but 
more studies have been needed, in particular in pediatric field. 
 
Interpretation of exhaled VOCs patterns: the breath fingerprint 
There are two types of methods to analyze the multidimensional pattern of 
exhaled VOCs. A direct method that compared the breathprint (BPs) of different 
groups and an indirect that observed BPs over the assessment of correlations 
between BP and known marker of a specified condition or disease. 
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Direct interpretation 
The graphical or numerical analysis of breath fingerprints offers a diagnostic 
indicator of a specified condition.  
There are alternative approaches: 
- The radar plot approach represents the individual BPs through the graphical 
displays of responses by the different sensors (fig. 8).  
 
 
Fig.8: Radar plot (from Scarlata et al., 2015) 
 
Each radar plot is formed by equiangular radii, each characterize the response of 
an individual sensor. The radius length is straight proportional to the size of the 
response. The radar plot ‘profile’ consists of a line drawn connecting the end of 
each radius. This approach has the advantage of providing comprehensive view of 
individual breath prints that permits a comparative analysis of different BPs and 
distinguishing behaviors of selected sensors (fig. 8) (Scarlata et al. 2015). 
Another method is evaluated simple histogram showing both directionality and 
extent of changes in BPs recorded by individual sensors (fig. 9) using box plots.  
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Fig. 9: Simple histogram 
 
This graphical presentation is well appropriate for analysis of changes in BPs. 
Analyzing box plots, many different characteristics of the data can be showed: 
statistical support for data pretreatment and cleaning, raw comparison of different 
populations, anomalous and/or prevalent contribution of some sensors (Scarlata et 
al. 2015). 
The more appropriate graphical representation to compare BPs of different 
populations is Principal Component Analysis (fig. 10) that evidence the clusters 
studied.  
 
Fig.10: Example of PCA blot 
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ELECTRONIC NOSE TECHNOLOGY IN RESPIRATORY DISEASES 
Electronic nose technology has been studied in different medical field, especially 
in respiratory disease in adult population. 
Nowadays only few studies evaluated this technology in pediatric population, so 
the use of this new technique in children must been evaluated (Benedek et al 
2013) as non-invasive and innovative method. 
 
Asthma 
The evidence of the use of e-nose in asthma diagnosis was described in different 
studies. Dragonieri et al evaluated mild and severe asthmatic adults from healthy 
controls (accuracy 100 and 90%, respectively) using e-nose technology 
(Dragonieri et al. 2007). Nevertheless, the e-nose could not efficiently distinguish 
mild from severe asthma (Dragonieri et al. 2007). Fens et al evaluated molecular 
profiling from adults with asthma and with COPD (accuracy 96%) and control 
subjects (Fens et al. 2009). Authors demonstrate a potential role of electronic 
noses in the differential diagnosis of obstructive airway diseases and in the risk 
assessment of asymptomatic smokers.  
Wagener et al. instead differentiated between eosinophilic and non-eosinophilic 
asthma with an accuracy of 85% (Wagener et al. 2013).  
In the last years Plaza et al. discriminated different asthma phenotypes 
(eosinophilic, neutrophilic, and paucigranulocytic) in induced sputum of 
asthmatics adult patients (Plaza et al. 2015) with e-nose. 
De Vries et al. have developed a standardized method to integrate e-nose 
technology with spirometry (Spiranose). This new technology discriminated 
controls and asthmatic, COPD and lung cancer with promising accuracy (de Vries 
et al. 2015). 
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Table 2: Studies on the breath analysis in asthma and COPD 
 (from Scarlata et al., 2015) 
 
Respiratory infection 
During the last years there was an increasing interest on exhaled VOCs profiling 
in respiratory infections disease. 
E-nose in correlation with a neural network system was tested to successfully 
identify mycobacterium tuberculosis but also anaerobic bacterial cultures in the 
blood (Pavlou et al. 2004). 
Lai et al. used e-nose to recognize upper respiratory infections and to differentiate 
the common upper respiratory bacterial pathogens (Staphylococcus aureus, 
Streptococcus pneumoniae, Haemophilus influenzae, and Pseudomonas 
aeruginosa) in vitro (Lai et al. 2002).  
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Other studies in vivo, evaluated exhaled breath of patients with pulmonary 
tuberculosis and controls with Cyranose 320. (Nakhleh et al. 2014). 
Thaler et al. identify the bacterial species in patients with sinusitis, and other 
authors evaluated VOCs profiling in the diagnosis of Ventilator Associated 
Pneumonia (VAP), aspergillosis in patients with cystic fibrosis and in subjects 
with prolonged chemotherapy-induced neutropenia (Thaler et al. 2005) (Hanson 
et al. 2005) (de Heer K et al. 2013).  
 
 
Table 3: Studies on breath analysis in respiratory infection 
 (from Scarlata et al., 2015) 
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Lung and pleural cancer 
Electronic nose has been used also to analyze patients with lung cancer and 
healthy controls as described by Di Natale et al (Di Natale et al. 2013).  
D’Amico et al., compared exhaled VOC spectrum of subjects with lung cancer 
and with other lung diseases (COPD, idiopathic pulmonary fibrosis, pulmonary 
arterial hypertension, and pulmonary sarcoidosis) obtaining an accuracy of 85.7% 
(D’Amico et al. 2010).  Similar values were obtained in patients with and without 
metabolic comorbidities, such as diabetes, obesity, and dyslipidemia and showed 
a large sensitivity to lung cancer at stage I with compared to other stages 
(II/III/IV) (Gasparri et al. 2016).  
These studies underline the importance of the application of this new technology 
for screening patients at early stages of lung cancer. 
Two studies evaluated e-nose technology in the field of Malignant Pleural 
Mesothelioma (MPM). Dragonieri et al. compare exhaled breath samples of 
patients with MPM in individuals professionally exposed to asbestos compared to 
healthy controls (Dragonieri et al. 2012). 
 
Obstructive Sleep Apnea Syndrome 
Several studies investigated exhaled VOC patterns using Cyranose 320 in 
detecting obstructive sleep apnea syndrome (OSAS) (Greulich et al.2013) 
(Benedek et al.  2013) (Kunos et al. 2015).  
Greulich et al. showed a significant difference between OSAS and healthy 
controls and also that exhaled VOC pattern changed after 3 months of CPAP 
therapy from untreated OSAS (Greulich et al.2013). 
Benedek et al. use e-nose in children and controls, showing an accuracy of 64% 
and an AUC of 0.83 (Benedek et al.  2013).  
Dragonieri et al. has distinguished between the exhaled profile of obese patients 
with OSAS from non-obese healthy controls but the e-nose could not extract VOC 
spectrum of obese patients with and without OSAS (Dragonieri et al. 2016). 
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Other Respiratory Diseases 
Other studies evaluated exhaled VOC profiles in other respiratory disease.  
Paff et al. evaluated the exhaled molecular profiles in patients with cystic fibrosis, 
primary ciliary dyskinesia, and controls (Paff et al. 2013).  
E-nose could also be applied in the field of lung transplant in the follow-up of 
lung transplant receivers (Kovacs et al. 2013). Moreover, e-nose help in the 
diagnostic tool of pulmonary embolism. Dragonieri et al. evaluated also patients 
with pulmonary sarcoidosis (Dragonieri et al. 2013).  
 
METHODS 
Aim of the study 
Primary objective: 
The primary objective of the study is to evaluate the feasibility of this new non-
invasive method in pediatric population.  
The electronic nose (e-nose) is an emerging technology that detects volatile 
organic compounds (VOCs) in exhaled breath. It uses sensors that react with 
different VOCs and generate a specific “breathprint” for each individual.  
In literature a limited study evaluated this method in pediatric care. 
This new technique could improve and promote early diagnosis and follow up in 
children with different diseases. 
We evaluated the capacity of children to properly perform the expiratory 
maneuver for collecting an exhaled air sample and if the ability to perform the 
technique will correlate with the patient's characteristics (age, gender, BMI). 
In this phase we evaluated also the limits and the possible changes that could be 
made in the collection method to make it applicable in the pediatric field. 
 
Secondary objective: 
The secondary objective is to investigate the existence of different respiratory 
patterns between a pediatric population with clinical and instrumental diagnosis of 
respiratory disease and a population of healthy children. 
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Study design 
The study was conducted at the Pediatric Respiratory Department of A.O.U.I 
Verona. 
This is a pilot study to evaluate the feasibility of new non-invasive technique, the 
electronic nose, in pediatric population. 
 
For the first objective, we enrolled 48 children aged between 6 and 16 years old 
(27 males and 21 females) who were conducted to the Pediatric Allergology and 
Pulmonary Clinic.  
Afterwards, this population, based on the objective examination and respiratory 
function tests, was divided into two groups: asthmatics and controls. 
Inclusion criteria for enrollment were: 
• Children of both sexes, aged between 6 and 16, who needed a pediatric broncho-
pneumologic outpatient visit; 
• Signature of informed consent by parents or legal guardian for participation in 
the study. 
Asthma was diagnosed according to the GINA guidelines. The classification of 
asthma was based on clinical history, physical examination, functional respiratory 
tests and the β2 agonist reversibility test. 
Exclusion criteria for both groups were: 
• Patients with oxygen therapy 
• Patient collaboration failure during biological collection 
• Presence of other chronic respiratory diseases other than asthma. 
The group of asthmatic patients was composed of 27 children, 16 males and 11 
females, while the control group consisted of 17 patients, 8 males and 9 females 
(table 4). 
At recruitment, after verifying the inclusion and exclusion criteria, physical 
examination for anthropometric measurements (height, weight, BMI), familiarity 
about asthma or allergies, skin prick test for diagnose allergic disease, evaluation 
of ongoing therapy and exposure to passive smoking have been collected. 
All children performed, lung function test and exhaled breath sampling collection. 
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The study was approved by the Ethical Committee of Verona and both children 
and their parents gave informed consent (CESC564). 
 
 Asthmatic Controls 
Total Number 27 17 
Male 16 8 
Female 11 9 
Medium age (yrs) 11.4 10.9 
Table 4: Patients characteristics 
 
For the second objective we enrolled we enrolled 47 children aged between 6 and 
16 years old (34 males and 13 females) who were conducted to the Pediatric 
Allergology and Pulmonary Clinic for respiratory disease (obstructive or 
restrictive disease). This population, based on the objective examination and 
respiratory function tests, was divided into four groups: patients with obstructive 
asthma (controlled, partially controlled, uncontrolled asthma) and restrictive 
pattern (congenital heart disease exposed to surgery) (fig.11). 
 
 Restrictive pattern Obstructive pattern Controls 
Total Number 9 28 10 
Male 8 22 3 
Female 1 6 6 
Medium age (yrs) 12 11 10 
Table 5: Patients characteristics 
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Fig.11: Study design 
 
Inclusion criteria for enrollment were: 
• Children of both sexes, aged between 6 and 16, who needed a pediatric broncho-
pneumologic outpatient visit; 
• Signature of informed consent by parents or legal guardian for participation in 
the study. 
Asthma was diagnosed according to the GINA guidelines. The classification of 
asthma was based on clinical history, physical examination, functional respiratory 
tests and the β2 agonist reversibility test. 
Restrictive pattern was diagnosing on clinical history, physical examination, 
functional respiratory tests in patients with congenital heart disease that have one 
or more surgery in early age.  
 
Exclusion criteria for both groups were: 
• Patients with oxygen therapy 
• Patient collaboration failure during biological collection 
• Presence of other chronic respiratory diseases other than asthma or restrictive 
disease. 
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At recruitment, after verifying the inclusion and exclusion criteria, physical 
examination for anthropometric measurements (height, weight, BMI), familiarity 
about asthma or allergies, skin prick test for diagnose allergic disease, evaluation 
of ongoing therapy and exposure to passive smoking have been collected. 
All children performed lung function test and exhaled breath sampling collection. 
 
Respiratory function 
Spirometry was performed following the American Thoracic Society (ATS) and 
the European Respiratory Society (ERS) guidelines, by a Masterscreen IOS 
(Jaeger; Wuerzburg, Germany) spirometer. It was calibrated daily with a 3L 
syringe (Cardinal Health; Germany 234 GmbH), to test the accuracy of volume 
measurement and to check ambient temperature and humidity.  
To evaluate bronchial reversibility, four separate doses (total dose 400 mcg) of 
salbutamol were delivered at 30 s intervals and the respiratory tests were repeated 
10–15 min after. Forced expiratory volume in one second (FEV1), forced vital 
capacity (FVC), maximum mid-expiratory flow (FEF25%–75%) and Tiffenau 
index (FEV1/FVC) were considered for the evaluations.  
 
Fig. 12: Spirometry 
 
Exhaled breath collection  
The patients breathed through a mouthpiece with the nose clipped into a 2-way 
non-rebreathing valve (Hans Rudolph 2700, Hans Rudolph, Kansas City, Mo) 
with an inspiratory VOC filter (HONEYWELL SPERIAN A2 ALUMINIUM 
FILTER CANISTER A2, North Safety, Middelburg, NL) and an expiratory silica 
reservoir to dry the expired air.   
The expiratory port was connected to a Tedlar bag.  
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The subject, connect with mouth to the system, performed an inspiratory capacity 
maneuver and exhaled the full expiratory vital capacity into the bag with an 
expiratory resistance of 20 cmH2O to close the soft palatum and to obtain an 
expiratory flow of 0.1 to 0.2 L/s.  Within 20 minutes, the bag was connected to the 
electronic nose for the analysis. 
 
Fig. 13: Exhaled breath collection 
 
Electronic nose 
Exhaled breath samples were analyzed by a commercially electronic nose 
(Cyranose 320; Smith Detections, Pasadena, Calif) with a nanocomposite array of 
32 organic polymer sensors.  
When these sensors are exposed to a mixture of VOCs the polymers are swelling, 
inducing a change in their electrical resistance. 
The changes in resistance of each of the 32 sensors produce data that are collected 
in an onboard database, producing a distribution (smellprint) that describes the 
VOC mixture and that can be used for pattern-recognition algorithms. 
 
 
Fig. 14: E-nose analysis 
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RESULTS 
Statistical analysis 
The signals of the 32 sensors for the 47 study patients were analyzed by PCA to 
reduce the data from 32 individual sensors to a set of five principal component 
scores aimed to finding the factors capturing the largest variance in the dataset. 
PCA was used as an exploratory analysis and was plotted in 2-dimensional graphs 
to visualize between-group separations.  
Once the PCA factors had been calculated, these factors were used to estimate 
penalized logistic regression for the construction of a pattern recognition 
algorithm (Friedman et al. 2010).  
Discrimination between patient groups were evaluated using the Area Under the 
Receiver Operating Characteristic curve (AUC-ROC). The graph below shows an 
example of three ROC curves representing excellent, good, and worthless 
diagnostic tests plotted on the same graph.  
 
 
 
The accuracy of the diagnostic test depends on how well the test separates the 
group being tested into those with and without the disease in question. Accuracy 
is measured by the area under the ROC curve. An area of 1 represents an excellent 
test; an area of 0.5 represents a bad test. A rough guide for classifying the 
accuracy of a diagnostic test is the traditional academic point system: 
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• 0.90 - 1 = excellent 
• 0 .80 - 0.90 = good 
• 0.70 - 0.80 = fair, moderately good 
• 0.60 - 0.70 = poor 
• 0.50 - 0.60 = bad 
The optimal cut-off on the ROC curve was estimated using the approach 
suggested in (Youden et al. 1950), which maximizes the Youden's J statistic: 
J = sensitivity + specificity – 1. 
 
Data were analyzed by Stata software version 15.0 (StataCorp. 2017. Stata 
Statistical Software: Release 15. College Station, TX: StataCorp LLC) and R version 
3.4.2 (R Core Team (2017). R: A language and environment for statistical computing. R 
Foundation for Statistical Computing, Vienna, Austria.https://www.R-project.org/). 
 
Evaluation of feasibility of the new method in pediatric population 
Electronic nose is a relatively recent method and, in the literature, only very few 
studies were conducted on pediatric subjects. However, one of these were 
conducted in subjected in mechanical ventilation, therefore data on spontaneous 
breathing patients are not available. 
The primary objective of our study was to evaluate the feasibility of this new non-
invasive method in the pediatric population.  
100% of the children examined were able to correctly perform the necessary 
maneuver for collecting the sample.  
This result, associated with low cost and ease of use, makes this method suitable 
for use in a pediatric clinical setting. 
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Analysis of the breathprint obtained 
For each of the 45 patients we observed the measurements provided by the 32 
sensors. The data matrix has 45 rows and 32 columns, and we first used a 
Heatmap chart.  
 
Fig.15: Heatmap chart 
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This type of representation associates different color to each numeral value of the 
matrix using a rule that is defined by the Color Key, represented at the left top of 
the chart. 
In this heatmap, two clusters have been applied: on the lines (patients) and on the 
columns (breathprint). The heatmap seems to identify two clusters of individuals 
based on their spectrum, one of which is characterized by higher values in S5, 
S31, S23 and S28 sensors (fig. 15). 
However, this subdivision does not coincide, even partially, with the two groups 
of controls and asthmatic patients in the study. 
We tried then to represent, in a two-dimensional graph, a first clustering with two 
groups, based on the breath using the Partitioning Around Medoids (PAM) 
method (fig. 16).  
 
 
Fig.16: Partitioning Around Medoids (PAM) method 
 
 
44 
 
On the aisles, the first two main components of a PCA are represented (the 
variability of subjects explained by these components is 95%) and the points are 
highlighted with different colors and symbols based on their clusters. 
Then we characterize the individual subjects within the two groups, focusing on 
specific characteristics of patients such as age, exposure to smoke and other 
characteristics. In this way, we noticed that the two clusters behaved differently 
depending on the ages considered.  
In children under the age of 9 years it is possible to differentiate them in the two 
clusters, asthmatics and controls. In older children this classification was not 
possible. The explanation of this behavior is probably linked with a bias on the 
volume of exhaled collect in the bags.  
In fact, the total expiratory volume of a young children (<9 years old) is about 1 
liter and consequently the 1L Tedlar bags are sufficient to contain the entire lung 
volume, this does not occur in older children with larger total exhalations 
volumes. In this case, the bags only contain the exhalation present in the upper 
airways and not the lower pathways most affected by the inflammatory processes. 
At this point we collected exhaled breath from children in three different Tedlar 
bags: 1 liter, 2 liters and 5 liters. 
We analyzed the more representative volume contains in the three different bags 
and define that in children aged 6-16 years the most suitable is 2 liters; and this 
was an important bias in the prior analysis. For the second objective, therefore, we 
used 2 liters Tedlar bags. 
 
Evaluation of the existence of different respiratory patterns in a pediatric 
population 
The subject characteristics of the 3 groups analyzed (obstructive, restrictive 
patterns and controls) are described in Table 5 and figure 11. Patients with 
obstructive pattern (asthma) were divided into 3 groups (controlled, partially 
controlled and uncontrolled asthma) about the symptoms controls. 
A sample of exhaled breath could be obtained in all subjects.  
The measurements were made in the same room with fixed temperature and 
humidity. A silica filter was used to limit the influence of humidity on the sensor 
45 
 
signals. Patients don’t eat any food, coffee, or other drinks during the 2 hours 
before the test. 
First, we examined whether exhaled breath from patients with restrictive pattern 
could be discriminated from others. 
The first graphical representation (fig. 17) obtained by PCA shows that patients 
with restrictive pattern have smellprints that significantly differ from those of the 
other patients for almost all the 32 nanosensors. In particular, the median value of 
the nanosensor signal is constantly higher for patients with restrictive pattern (fig. 
17-18-19). 
 
 
 
Fig. 17: Graphical representation of smellprint median values in the 32 nanosensors for 
patients with restrictive pattern (red line) and other patients (blue line) 
46 
 
 
Fig. 18: Boxplot of smellprints of 32 nanosensor 
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Fig. 19: Radar plot of smellprint median values for the untransformed (A) and 
standardized (B) signals of the 32 sensors. 
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Principal component analysis (PCA) was performed on unstrasformed data and 
the first 5 principal component scores were calculated. 
A penalized logistic regression model for discriminating patients with restrictive 
pattern was estimated using the 5 PC scores. The selected scores were the first 
(Score1) and the fifth (Score5) (fig. 21). The decision rule given by the penalized 
model was:  
if (Score5-0.01972441*Score1- 0.0008513515>0) then (patient=Restrictive)  
otherwise (patient=Other) 
The area under the ROC curve for this model was 0.84 (95%CI= 0.67 – 1.00, 
P<0.001). The sensitivity and specificity of the model at the Youden cutpoint 
were 0.78 and 0.95, respectively. 
 
 
 
 
Fig. 20: Graphical visualization of the discriminative ability of the proposed predictive 
logistic model. The dashed line represents the discrimination curve of the model. Score1 
and Score3 are the predictive PC scores used in the model 
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Fig. 21. Receiver operating characteristic (ROC) curve for the penalized logistic 
regression model aimed to discriminate between exhaled biomarker profiles of restrictive 
patients and controls. 
 
Afterwards, we examined whether exhaled breath from patients with obstructive 
pattern could discriminate patients with controlled or not controlled asthma. 
The first graphical representation (fig. 22) obtained by PCA shows that 
asymptomatic (control patients and patients with controlled asthma pattern 
C+AC) have smellprints of the sensor 20 (S20) that significantly differ from those 
symptomatic (asthma partially controlled and not controlled, APC+ANC). In 
particular, the median value of signal of S20 is higher for C+AC patients. 
 
Fig. 22: Graphical representation of smellprint median values in the 32 nanosensors for 
control patients and patients with controlled asthma (red line) and partially controlled or 
uncontrolled asthma patients (blue line) 
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Fig.23: Radar plot of smellprint median values for the untransformed (A) and 
standardized (B) signals of the 32 sensors.  
A 
B 
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Fig. 24.: Boxplot of smellprints of sensor 20 (S20) 
 
 
  
 
Fig. 25: Graphical visualization of the discriminative ability of the proposed predictive 
logistic model. The dashed line represents the discrimination curve of the model. Score2 
and Score3 are the predictive PC scores used in the model 
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Fig. 26: Receiver operating characteristic (ROC) curve for the penalized logistic 
regression model aimed to discriminate between exhaled biomarker profiles of 
 AC+C vs APC+ANC 
 
Principal component analysis (PCA) was performed on untransformed data and 
the first 5 principal component scores were calculated. 
A penalized logistic regression model for discriminating AC+C patients was 
estimated using the 5 PC scores. The selected scores were the second (Score2) and 
the third (Score3) (fig. 26). The decision rule given by the penalized model was:  
if (Score3+0.000134485>0) then (patient=AC+C) 
 otherwise (patient=ANC+APC) 
The area under the ROC curve for this rule was 0.81 (95%CI= 0.67 – 0.95, 
P<0.001). The sensitivity and specificity of the model at the Youden cutpoint 
were 0.78 and 0.95, respectively. 
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DISCUSSION 
The electronic nose (e-Nose) is an innovative biomimetic technology that 
simulates the olfactive system to identify compounds in different samples with 
complex data analysis system and processing algorithms. 
This technique has been applied for the characterization of various pathologies 
(sarcoidosis, COPD, OSAS and others), as reported in some studies on adult 
patients. In literature, only a study was conducted on pediatric subjects in 
spontaneous breathing. 
The primary objective of our study was to evaluate the feasibility of this new non-
invasive method in the pediatric population. 100% of the children examined were 
able to correctly perform the necessary maneuver for collecting the sample. This 
result, coupled with low cost and ease of use, makes this method suitable for use 
in a pediatric clinical setting. 
Based on the results obtained in adults by Dragonieri (Dragonieri et al. 2007) and 
his team, the next goal of our study was to identify different respiratory patterns in 
a pediatric population with clinical and instrumental diagnosis of obstructive or 
restrictive disease and a population of healthy children. 
However, the smellprint obtained through e-nose analysis showed the presence of 
two distinct clusters of patients without any correlation, even partial, with the 
previous subdivision of children into asthmatics and controls. 
At this point we re-analyzed the possible bias that influence the practical 
technique to collect the exhaled breath sample.  
We characterized the individual subjects within the two cluster, focusing on age, 
exposure to smoke and other characteristics. In this way, we noticed that the two 
clusters behaved differently depending on the ages considered. 
The bias found was linked to the exhalation volume collected in the bags used of 
1-liter Tedlar bags. In fact, if the total expiratory volume of young children is 
quite small and consequently the 1L sachets are sufficient to contain the entire 
lung volume, this does not occur in older children. Probably the 1 L bags in older 
children only contain the exhalation present in the upper airways and not in the 
lower ones. 
The size of the bags can be considered the first limit of this new pediatric method. 
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Therefore, in the second phase of our study we used bigger Tedlar bags (2 L) to 
collect exhaled breath sample. 
Our study shows that electronic nose can discriminate exhaled breath of patients 
with restrictive pattern from others. Moreover, in the group of obstructive 
patterns, the electronic nose could adequately discriminate between symptomatic 
and asymptomatic asthmatic patients. These findings indicate that the mixture of 
exhaled volatile organic compounds is different in different respiratory 
inflammation forms.  
To our knowledge, this is the first study using pattern analysis of exhaled VOC 
mixtures in exhaled breath in pediatric population. Interestingly, we observed a 
complete separation of smellprints between patients with restrictive pattern and 
other groups as well as between symptomatic patients in obstructive pattern.  
Nowadays, electronic noses have been used in a variety of medical fields, 
including the detection of sinusitis, respiratory disease, urinary tract infections, 
cancers and diabetes mellitus.  
The application of electronic noses in respiratory disease showed high specificity 
and moderate sensitivity in the identification of lung cancer and high accuracy in 
the diagnosis of tuberculosis infections and pneumoniae.  
Therefore, the analysis of VOCs present in exhaled breath may be an important 
source of biomarkers for the diagnosis of respiratory diseases, including asthma 
especially in pediatric population. 
In this study, attention was paid to methodologic aspects such as the collection of 
the sample and selection of pediatric patients. 
This is the one of the first studies, to our knowledge, where exhaled breath 
samples collected from children were successfully analyzed by an E-nose. 
All the patients were well characterized by using subjective and objective criteria 
such as the presence of symptoms, reversible airways obstruction or restrictive 
characteristics.  
Patients with controlled and uncontrolled asthma were selected based on their 
medication use, lung function and asthma symptoms control.  
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All subjects inhaled VOC filtered air then exhaled in a flow- and pressure-
controlled way to close soft palate and the dead space to collected breath 
originates from the alveolar region.  
E-noses were able to discriminate breath samples of patients with bronchial 
asthma (Dragonieri et al. 2007), BPCO (Fens et al. 2009) and OSAS (Greulich et al. 
2012). For the first time, we used breath analysis in pediatric patients with 
obstructive and restrictive disease. The biomarker profile of breath collected from 
the lower airways in children with obstructive and restrictive airways pattern and 
controls were analyzed by e-nose. 
In our study the electronic nose was not able to make a clear distinction between 
controlled, partially controlled and uncontrolled asthma and controls but only 
between controls and asthma controlled (C+AC) and partially and uncontrolled 
asthma (APC+ANC). This may suggest that the state of bronchial inflammation 
related to clinical manifestations probably are the major determinant of exhaled 
breath smellprints. 
However, our results suggest that new studies with higher sample sizes may be 
required to obtain optimal results by electronic noses in pediatric patients with 
various asthma patterns.  
Volatile compounds are cellular metabolites produced during multiple pathways 
in inflammation-related oxidative stress in the airways (Miekisch et al. 20004). 
Additionally, the composition of exhaled breath is also influence by volatile 
substances from the blood stream to the alveolar space.  
Recent studies described how e-nose can identify exhaled biomarker pattern and 
the associations between airway and systemic inflammatory markers (Fens et al. 
2011).  
Other analytical methods to define VOCs in exhaled breath are gas 
chromatography/mass spectrometry (GC-MS) or magnetic resonance 
spectroscopy (Boots et al. 2012).   
More than 3000 different VOCs are being evaluated by GC-MS analysis in the 
human exhaled breath. The use of an inspiratory VOC filter permits to detected 
VOCs derived from physiologic and pathophysiologic metabolic pathways (Moser 
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et al. 2005). These derives from the airways and the lungs or can represent 
systemic metabolites from elsewhere in the body.  
The markers in exhaled breath are influenced by the change of several metabolic 
pathways during chronic airways inflammation (Kharitonov et al. 2001). For 
instance, asthma is associated with elevated levels of pentane, markers of 
oxidative stress and eicosanoids in exhaled breath condensate (Paredi et al. 2000). 
Our results demonstrate that exhaled biomarker pattern can be collected in a 
pediatric population and can distinguished children with lung obstructive and 
restrictive disease, suggesting that airway and systemic metabolic changes are 
present in the diseases. Further large-scale studies are needed to validate our 
results and investigate exhaled biomarker pattern analysis by an E-nose as an 
additional tool in monitoring airway inflammation in children with airways 
disease.  
We acknowledge the limits of the study. The number of patients recruited is 
relatively small therefore validation studies for exhaled breath pattern 
discrimination should include a higher number of children to better discriminate 
different obstructive pattern. 
Electronic is a handheld, non-invasive, rapid and feasible in children device that 
make this tool suitable for pediatric clinical practice. In addition, validation of 
electronic noses in other diseases, not only on exhaled breath, seems to be 
mandatory.   
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